JPM26: Novo Refocuses on Diabetes and Obesity Amid Push To Expand GLP-1 Market

By /

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, obesity or overweight.

Scroll to Top